These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3471288)

  • 1. Strontium-89 therapy: strontium kinetics and dosimetry in two patients treated for metastasising osteosarcoma.
    Blake GM; Zivanovic MA; McEwan AJ; Condon BR; Ackery DM
    Br J Radiol; 1987 Mar; 60(711):253-9. PubMed ID: 3471288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strontium-89 radionuclide therapy: a dosimetric study using impulse response function analysis.
    Blake GM; Gray JM; Zivanovic MA; McEwan AJ; Fleming JS; Ackery DM
    Br J Radiol; 1987 Jul; 60(715):685-92. PubMed ID: 3620827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of human biokinetics of strontium on internal ingestion dose of 90Sr and absorbed dose of 89Sr to organs and metastases.
    Li WB; Höllriegl V; Roth P; Oeh U
    Radiat Environ Biophys; 2008 Apr; 47(2):225-39. PubMed ID: 18204850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma.
    Breen SL; Powe JE; Porter AT
    J Nucl Med; 1992 Jul; 33(7):1316-23. PubMed ID: 1613572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate.
    Blake GM; Zivanovic MA; McEwan AJ; Ackery DM
    Eur J Nucl Med; 1986; 12(9):447-54. PubMed ID: 3102236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
    Brundage MD; Crook JM; Lukka H
    Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone pain palliation with strontium-89 in cancer patients with bone metastases.
    Giammarile F; Mognetti T; Resche I
    Q J Nucl Med; 2001 Mar; 45(1):78-83. PubMed ID: 11456379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 89Sr radionuclide therapy: dosimetry and haematological toxicity in two patients with metastasising prostatic carcinoma.
    Blake GM; Zivanovic MA; McEwan AJ; Batty VB; Ackery DM
    Eur J Nucl Med; 1987; 13(1):41-6. PubMed ID: 3109917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling of internal dose distributions during SR-89 treatment of a patient with bone metastases.
    Bialkowski MM; Wierzbicki JG; Porter AT
    Cancer Biother Radiopharm; 1997 Oct; 12(5):355-62. PubMed ID: 10851487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective use of strontium-89 in osseous metastases.
    Kuroda I
    Ann Nucl Med; 2012 Apr; 26(3):197-206. PubMed ID: 22160737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Strontium-89 for bone metastases from prostate cancer: an update].
    Zhao WW; Xie P; Deng HF
    Zhonghua Nan Ke Xue; 2010 Mar; 16(3):269-72. PubMed ID: 20369560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strontium kinetics in metastasized prostatic carcinoma: a comparison with the predictions of impulse response function analysis.
    Blake GM; Zivanovic MA; Gray JM
    Nucl Med Commun; 1987 Nov; 8(11):909-19. PubMed ID: 3441327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radionuclide-targeted therapy for the management of metastatic bone pain.
    Ackery D; Yardley J
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):27-31. PubMed ID: 7684862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
    Ma YB; Yan WL; Dai JC; Xu F; Yuan Q; Shi HH
    Zhonghua Nan Ke Xue; 2008 Sep; 14(9):819-22. PubMed ID: 18998467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autopsy of a cadaver containing strontium-89-chloride.
    Schraml FV; Parr LF; Ghurani S; Silverman ED
    J Nucl Med; 1997 Mar; 38(3):380-2. PubMed ID: 9074523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strontium-89 for palliation of bone pain.
    Gompakis N; Triantafyllou P; Sidi B; Koliouskas ED; Salem N; Pistevou K
    Med Pediatr Oncol; 2003 Feb; 40(2):136. PubMed ID: 12461806
    [No Abstract]   [Full Text] [Related]  

  • 17. Bone pain palliation with 85Sr therapy.
    Giammarile F; Mognetti T; Blondet C; Desuzinges C; Chauvot P
    J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent dendritic cell vaccine and strontium-89 radiation therapy in the management of multiple bone metastases.
    Liu J; Li J; Fan Y; Chang K; Yang X; Zhu W; Wu X; Pang Y
    Ir J Med Sci; 2015 Jun; 184(2):457-61. PubMed ID: 24876093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Strontium chloride (89Sr-chloride) fractional injection method for bone metastases treatment].
    Fomin DK; Smirnov IuN; Tararukhina OB; Nazarov AA
    Vopr Onkol; 2012; 58(1):116-8. PubMed ID: 22629840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum compounds as radiosensitizers in strontium-89 metabolic radiotherapy.
    Sciuto R; Festa A; Tofani A; Pasqualoni R; Semprebene A; Cucchi R; Ferraironi A; Rea S; Maini CL
    Clin Ter; 1998; 149(921):43-7. PubMed ID: 9621488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.